Zobrazeno 1 - 10 of 42 pro vyhledávání: '"Christian, de Bodinat"'
2
Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study
Autor: Oleg S. Chaban, Celine Gruget, Christian de Bodinat, Antti Ahokas, A. Avedisova, F. Picarel-Blanchot, Marek Jarema, Dan J. Stein, Valérie Olivier, Livia Vavrusova
Publikováno v: European Neuropsychopharmacology. 27:526-537
Agomelatine is efficacious in reducing symptoms and preventing relapse in placebo-controlled trials in generalised anxiety disorder (GAD). Nevertheless, fixed dose studies of agomelatine in GAD have not been undertaken. To determine the minimally eff
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b68c66cbd85faa0081206b315846c69
https://doi.org/10.1016/j.euroneuro.2017.02.007
Zobrazit plný text záznamu
3
Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France
Autor: Jacques Benichou, Marie-Cécile Secouard, Philip Gorwood, Xavier Desobry, F. Picarel-Blanchot, Christian de Bodinat, Nicolas Moore, Marine Wattez
Publikováno v: Clinical Drug Investigation
Clinical Drug Investigation, Springer Verlag, 2020, ⟨10.1007/s40261-020-00957-9⟩
Clinical Drug Investigation, 2020, ⟨10.1007/s40261-020-00957-9⟩
Background and Objectives Non-interventional studies are a valuable source of evidence that is complementary to traditional randomised, blinded and controlled clinical trials, for evaluating antidepressants in a real-world setting. The aim of the pre
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::630908fb98fc2e1178bfe86f783a8134
http://hdl.handle.net/20.500.12278/26013
Zobrazit plný text záznamu
4
Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months
Autor: Carole Belaïdi, Christian de Bodinat, Alla Avedisova, F. Picarel-Blanchot, Sidney H. Kennedy
Publikováno v: European Neuropsychopharmacology. 26:378-389
This randomized placebo-controlled "dose relation study" was conducted in patients who met criteria for major depressive disorder, to evaluate the efficacy and safety of agomelatine during 24 weeks at 3 doses (i) low fixed dosage (10 mg/day, n=100 pa
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6519d190dd30a94991916e6fe68c9a0
https://doi.org/10.1016/j.euroneuro.2015.09.006
Zobrazit plný text záznamu
5
Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: Randomised double-blind placebo-controlled trial
Autor: Lakshmi N, Yatham, Eduard, Vieta, Guy M, Goodwin, Michel, Bourin, Christian, de Bodinat, Judith, Laredo, Joseph, Calabrese, L, Yatham
Publikováno v: British Journal of Psychiatry. 208:78-86
BackgroundAdjunctive antidepressant therapy is commonly used to treat acute bipolar depression but few studies have examined this strategy.AimsTo examine the efficacy of agomelatine v. placebo as adjuncts to lithium or valproate in bipolar depression
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1505f2463259fa4bc08a7f04ae5dfa7
https://doi.org/10.1192/bjp.bp.114.147587
Zobrazit plný text záznamu
6
12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder
Autor: Sergey Mosolov, F. Picarel-Blanchot, Valérie Olivier, Livia Vavrusova, Antti Ahokas, István Bitter, Michael Bauer, Sophie Matharan, Dan J. Stein, Jon Paul Khoo, Marek Jarema, Michael Van Ameringen, Cyril Hӧschl, Christian de Bodinat
Publikováno v: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 28(8)
Treatment of severely symptomatic patients with generalized anxiety disorder (GAD) raises particular concerns for clinicians. This 12-week double-blind study evaluated the efficacy of agomelatine (25–50 mg/day) in the treatment of patients with sev
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27c53ffb1887872f8e49be292614a456
https://pubmed.ncbi.nlm.nih.gov/30135032
Zobrazit plný text záznamu
7
Antidepressant effect in older depressed patients: the lessons of two agomelatine trials
Autor: Reinhard Heun, Christian de Bodinat, Patrice Boyer, Guy M. Goodwin, Pierre Thomas, F. Picarel-Blanchot
Publikováno v: International Clinical Psychopharmacology
International Clinical Psychopharmacology, 2017, International Clinical Psychopharmacology, 32 (4), pp.184-194. ⟨10.1097/YIC.0000000000000174⟩
The present paper reports in parallel the findings of the two phase III trials that evaluated the efficacy of agomelatine in older depressed patients. It describes how the particular methodological innovations (particularly in relation to patient sel
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6a80041295c49b1564b4edbfb9d63ac
https://hal.univ-lille.fr/hal-02351285
Zobrazit plný text záznamu
8
How to switch to agomelatine after an unsuccessful try with paroxetine or venlafaxine
Autor: Sophie Matharan, Christian de Bodinat, Michel Lejoyeux
Publikováno v: CNS Spectrums. 20:29-38
Objective/introductionThe present trial informs clinicians about switching conditions with the antidepressant agomelatine after the failure of a treatment with either paroxetine or venlafaxine.MethodsThe total number of discontinuation-emergent sympt
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8a88d31fc73518d28f4ca49dbb15ce8
https://doi.org/10.1017/s1092852913000813
Zobrazit plný text záznamu
9
Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine
Autor: Christian de Bodinat, Frédéric Rouillon, Guy M. Goodwin, Robin Emsley, Patrice Boyer
The present paper reports in parallel the findings of the two studies that evaluated the efficacy of agomelatine in preventing relapse of depression. It describes the methodological adjustments made between the first and the second trial, particularl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e9609cb8b4b47ac5a2ab5eea17e095f
https://doi.org/10.1097/yic.0b013e32835b0814
Zobrazit plný text záznamu
10
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development
Autor: Millan Mark, Beatrice Guardiola-Lemaitre, Carmen Muńoz, Christian de Bodinat, Pierre Renard, Elisabeth Mocaer
Publikováno v: Nature Reviews Drug Discovery. 9:628-642
Current management of major depression, a common and debilitating disorder with a high social and personal cost, is far from satisfactory. All available antidepressants act through monoaminergic mechanisms, so there is considerable interest in novel
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4610e3c2478d34073d1ad476ec78b987
https://doi.org/10.1038/nrd3140
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje